Summary:
This clinical research study is being conducted worldwide to test the long-term benefits of the study drug versus placebo in reducing lung and heart complications. The study drug is a new drug that combines both a long-acting beta-agonist and corticosteroid in a single inhaler in order to relax the airways in the lung, helping to make breathing easier.
Qualified Participants Must:
• Have a diagnosis of moderate COPD
•
Have a history or risk of heart disease
Be between 40 and 80 years of age
•
Be a current or former cigarette smoker
Qualified Participants May Receive:
Direct access to study doctor or nurses who will answer questions and concerns, study-related physical exams, blood work and other laboratory services and investigational study drug.
If you qualify, compensation for time and travel may be available.